DNA aptamers against exon v10 of CD44 inhibit breast cancer cell migration

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Iida, Joji ^a   Clancy, Rebecca ^a   Dorchak, Jesse ^a   Somiari, Richard I ^b   Somiari, Stella ^a   Cutler, Mary Lou ^c   Mural, Richard J ^a   Shriver, Craig D ^d  

^a WINDBER RESEARCH INSTITUTE   (United States)

^b ITSI Biosciences   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; DNA; DNA APTAMER; EPHRIN RECEPTOR A2; HERMES ANTIGEN; UNCLASSIFIED DRUG; PEPTIDE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL MIGRATION; CELL SURFACE; COMBINATORIAL CHEMISTRY; COMPLEX FORMATION; CONTROLLED STUDY; EXON; FEMALE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PROTEIN FUNCTION; RECEPTOR BINDING; BREAST TUMOR; CELL MOTION; DISEASE COURSE; ENZYME SPECIFICITY; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, CD44; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; EXONS; HUMANS; PEPTIDES; RECEPTOR, EPHA2; SELEX APTAMER TECHNIQUE; SUBSTRATE SPECIFICITY;

EID: 84896772168     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088712     Document Type: Article

References (47)

1. Ferreira CS, Matthews CS, Missailidis S (2006) DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumour Biol 27: 289-301. (Pubitemid 44646223)
2. Fitzwater T, Polisky B (1996) A SELEX primer. Methods Enzymol 267: 275-301. (Pubitemid 26159229)
3. Lupold SE, Hicke BJ, Lin Y, Coffey DS (2002) Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 62: 4029-4033. (Pubitemid 34791070)
4. Kimoto M, Shirouzu M, Mizutani S, Koide H, Kaziro Y, et al. (2002) Anti-(Raf-1) RNA aptamers that inhibit Ras-induced Raf-1 activation. Eur J Biochem 269: 697-704. (Pubitemid 34128029)
5. Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L (2003) A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci U S A 100: 15416-15421. (Pubitemid 38021004)
6. Hicke BJ, Marion C, Chang YF, Gould T, Lynott CK, et al. (2001) Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem 276: 48644-48654.
7. Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, et al. (2009) RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther 17: 153-161.
8. Ahmad KM, Oh SS, Kim S, McClellen FM, Xiao Y, et al. (2011) Probing the limits of aptamer affinity with a microfluidic SELEX platform. PLoS One 6: e27051.
9. Li N, Nguyen HH, Byrom M, Ellington AD (2011) Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS One 6: e20299.
10. Jeong S, Han SR, Lee YJ, Kim JH, Lee SW (2010) Identification of RNA aptamer specific to mutant KRAS protein. Oligonucleotides 20: 155-161.
11. Borbas KE, Ferreira CS, Perkins A, Bruce JI, Missailidis S (2007) Design and synthesis of mono- and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer. Bioconjug Chem 18: 1205-1212. (Pubitemid 47122643)
12. Ferreira CS, Papamichael K, Guilbault G, Schwarzacher T, Gariepy J, et al. (2008) DNA aptamers against the MUC1 tumour marker: design of aptamer-antibody sandwich ELISA for the early diagnosis of epithelial tumours. Anal Bioanal Chem 390: 1039-1050. (Pubitemid 351207802)
13. Pieve CD, Perkins AC, Missailidis S (2009) Anti-MUC1 aptamers: radiolabelling with (99 m) Tc and biodistribution in MCF-7 tumour-bearing mice. Nucl Med Biol 36: 703-710.
14. Bell C, Lynam E, Landfair DJ, Janjic N, Wiles ME (1999) Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim 35: 533-542. (Pubitemid 29530104)
15. Carrasquillo KG, Ricker JA, Rigas IK, Miller JW, Gragoudas ES, et al. (2003) Controlled delivery of the anti-VEGF aptamer EYE001 with poly (lactic-coglycolic) acid microspheres. Invest Ophthalmol Vis Sci 44: 290-299. (Pubitemid 36134287)
16. Gragoudas ES, Adamis AP, Cunningham ET, Jr., Feinsod M, Guyer DR (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816. (Pubitemid 40051904)
17. Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN, Jr., et al. (2013) A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New Drugs.
18. Naor D, Sionov RV, Ish-Shalom D (1997) CD44: structure, function, and association with the malignant process. Adv Cancer Res 71: 241-319. (Pubitemid 27197761)
19. Iida N, Bourguignon LY (1995) New CD44 splice variants associated with human breast cancers. J Cell Physiol 162: 127-133.
20. Iida N, Bourguignon LY (1997) Coexpression of CD44 variant (v10/ex14) and CD44S in human mammary epithelial cells promotes tumorigenesis. J Cell Physiol 171: 152-160. (Pubitemid 27205056)
21. Kan M, Aki M, Akiyama K, Naruo S, Kanayama H, et al. (1995) High-level expression of the CD44 variant sharing exon v10 in renal cancer. Jpn J Cancer Res 86: 847-853.
22. Freyschmidt-Paul P, Seiter S, Zoller M, Konig A, Ziegler A, et al. (2000) Treatment with an anti-CD44v10-specific antibody inhibits the onset of alopecia areata in C3H/HeJ mice. J Invest Dermatol 115: 653-657.
23. Rosel M, Khaldoyanidi S, Zawadzki V, Zoller M (1999) Involvement of CD44 variant isoform v10 in progenitor cell adhesion and maturation. Exp Hematol 27: 698-711. (Pubitemid 29181446)
24. Zoller M, Gupta P, Marhaba R, Vitacolonna M, Freyschmidt-Paul P (2007) Anti-CD44-mediated blockade of leukocyte migration in skin-associated immune diseases. J Leukoc Biol 82: 57-71. (Pubitemid 47026416)
25. Iida J, Dorchak J, Lehman JR, Clancy R, Luo C, et al. (2012) FH535 inhibited migration and growth of breast cancer cells. PLoS One 7: e44418.
26. Iida J, Wilhelmson KL, Ng J, Lee P, Morrison C, et al. (2007) Cell surface chondroitin sulfate glycosaminoglycan in melanoma: role in the activation of pro-MMP-2 (pro-gelatinase A). Biochem J 403: 553-563. (Pubitemid 46706984)
27. Iida J, Pei D, Kang T, Simpson MA, Herlyn M, et al. (2001) Melanoma chondroitin sulfate proteoglycan regulates matrix metalloproteinase-dependent human melanoma invasion into type I collagen. J Biol Chem 276: 18786-18794.
28. Eisenmann KM, McCarthy JB, Simpson MA, Keely PJ, Guan JL, et al. (1999) Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. Nat Cell Biol 1: 507-513. (Pubitemid 129503671)
29. Olsson E, Honeth G, Bendahl PO, Saal LH, Gruvberger-Saal S, et al. (2011) CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 11: 418.
30. Murohashi M, Hinohara K, Kuroda M, Isagawa T, Tsuji S, et al. (2010) Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells. Br J Cancer 102: 206-212.
31. Kalish ED, Iida N, Moffat FL, Bourguignon LY (1999) A new CD44V3-containing isoform is involved in tumor cell growth and migration during human breast carcinoma progression. Front Biosci 4: A1-8.
32. Holm R, de Putte GV, Suo Z, Lie AK, Kristensen GB (2008) Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis. Int J Med Sci 5: 121-126. (Pubitemid 351880763)
33. Petty A, Myshkin E, Qin H, Guo H, Miao H, et al. (2012) A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS One 7: e42120.
34. Tandon M, Vemula SV, Mittal SK (2011) Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets 15: 31-51.
35. Huang F, Reeves K, Han X, Fairchild C, Platero S, et al. (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67: 2226-2238. (Pubitemid 46424242)
36. Noblitt LW, Bangari DS, Shukla S, Knapp DW, Mohammed S, et al. (2004) Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther 11: 757-766. (Pubitemid 39488474)
37. Berner HS, Nesland JM (2001) Expression of CD44 isoforms in infiltrating lobular carcinoma of the breast. Breast Cancer Res Treat 65: 23-29. (Pubitemid 32163496)
38. Saleh F, Reno W (2008) Invasive cribriform breast carcinomas in patients with grade 1 and stage IIA (T2 N0 M0) breast cancer strongly express the v3 and v6, but not the v4 isoforms of the metastatic marker CD44. Neoplasma 55: 246-255.
39. Krishnamachary B, Penet MF, Nimmagadda S, Mironchik Y, Raman V, et al. (2012) Hypoxia regulates CD44 and its variant isoforms through HIF-1alpha in triple negative breast cancer. PLoS One 7: e44078.
40. Fox BP, Kandpal RP (2004) Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun 318: 882-892. (Pubitemid 38625856)
41. Nakamoto M, Bergemann AD (2002) Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech 59: 58-67.
42. Pasquale EB (2010) Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 10: 165-180.
43. Famulok M, Hartig JS, Mayer G (2007) Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy. Chem Rev 107: 3715-3743. (Pubitemid 47534316)
44. Weiss S, Proske D, Neumann M, Groschup MH, Kretzschmar HA, et al. (1997) RNA aptamers specifically interact with the prion protein PrP. J Virol 71: 8790-8797. (Pubitemid 27446463)
45. Xu W, Ellington AD (1996) Anti-peptide aptamers recognize amino acid sequence and bind a protein epitope. Proc Natl Acad Sci U S A 93: 7475-7480. (Pubitemid 26277059)
46. Somasunderam A, Thiviyanathan V, Tanaka T, Li X, Neerathilingam M, et al. (2010) Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44. Biochemistry 49: 9106-9112.
47. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767.